Plasma EIF4A3 levels were higher in HCC patients compared to controls and NAFLD patients (Figure 2L), suggesting that EIF4A3 might serve as an early biomarker for HCC development. This evidence concerns the gene EIF4A3 and metabolic dysfunction-associated steatotic liver disease.